The expressions ofCD8A,CXCL9,NKX2-1,SFTA3,IDO1, andIL2RB in the response group was markedly higher, suggesting that six M1 genes were indeed involved in NSCLC sensitivity to camrelizumab plus chemotherapy (Figure 6A‒F). The gene discussed is CXCL9; the disease is non-small cell lung carcinoma.